Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Vets Emergency Ebola Funding Request, Including Diagnostics, PPE

This article was originally published in The Gray Sheet

Executive Summary

The Senate Appropriations Committee vetted a $6.18 billion request for emergency funding from the Obama administration, including funds to accelerate and approve Ebola diagnostics and to buy personal protective equipment.

You may also be interested in...



CDRH Would Get $7 Million More Under President’s 2016 Request

President Obama requests $7 million more for CDRH in 2016, a modest boost over 2015’s $321 million level, but Senate Finance Committee Chair Orrin Hatch, R-Utah, calls the added funds a “non-starter” in the new Congress. The request reflects new dollars for a Precision Medicine Initiative, and a ten-fold increase in antibiotic resistance testing, a cross-agency effort called ‘Project Bioshield’, said CDC Director Thomas Frieden and FDA Commissioner Margaret Hamburg.

Obama Urges End To Corporate Inversions

In his State of the Union speech, the President pledged to “close tax loopholes,” including his continuing efforts to ban U.S. firms from moving their tax headquarters overseas in corporate inversion deals. On the same day Democratic legislators introduced a bill to stop corporate inversions. Finance Panel Chair Sen. Orrin Hatch, R-Utah, has different tax loopholes he wants to close.

FDA Funding Up Slightly In 2015 Funding BiIl, But Device Dollars Stay Flat

Spending agreement would give FDA about a 1.3 percent increase from fiscal year 2014, in part due to a $25 million one-time increase targeted at the Ebola crisis, but funding for device activities would remain flat at $420.55 million.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel